Other languages Immutep Limited

Equities

IMM

AU000000IMM6

Delayed Australian S.E. Other stock markets 08:07:01 2024-04-29 pm EDT			5-day change	1st Jan Change
0.435 ^AUD	-2.25%		+12.99%	+26.09%

Apr. 24	Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	MT
Apr. 24	Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	Apr. 24
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	Apr. 24
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	Apr. 18
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	Apr. 17
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	Mar. 05
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	Feb. 27
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer	Jan. 04
Immutep Doses First Patient in Cancer Trial	Jan. 03
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Dec. 21
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government	Dec. 07
Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment	Nov. 22
Immutep Expands Sites for Phase 1 Cancer Trial	Nov. 22
Immutep Limited Announces Completion of Patient Enrollment in the Tacti-003 (Keynote-Pnc-34) Phase Iib Trial	Nov. 09
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	Nov. 09
Immutep Completes Enrollment for Phase 2b Cancer Trial	Nov. 09
Immutep Limited Announces Completion of the Safety Lead-In and Opening of the Randomized Phase Ii of the Aipac-003 Phase II/III Trial in Metastatic Breast Cancer	Nov. 06
Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer	Nov. 03
Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023	23-10-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immutep Limited

Equities

IMM

AU000000IMM6

Other languages

Filters